Nanobody-TurboID Maps the CD38 Surfaceome

Cell-surface proteins rarely act in isolation. Their functions emerge from nanoscale neighborhoods that coordinate signal transduction, adhesion, membrane organization, extracellular-matrix interactions, and migration. The pre-proof study by Feng and colleagues, Exploring the CD38-associated surfaceome via nanobody-targeted TurboID, addresses this spatial problem by developing nanobody-targeted TurboID, or NBID, for protein-proximity mapping on living cells.

Study Background and Research Question

CD38 is a cell-surface glycoprotein with enzymatic and signaling relevance in immune biology, cancer, and tissue interactions. Its activity is likely influenced by the proteins that surround it, yet conventional affinity purification can miss transient, weak, or spatially restricted associations. A biochemical interaction detected after cell lysis may also fail to distinguish direct binding from proteins that occupy the same membrane region.

The reference study therefore asks a focused question: which proteins reside close to CD38 in the native plasma membrane, and do these proximal proteins help explain CD38-associated cell behavior? The authors examine this question in live adherent cultures rather than relying exclusively on isolated protein complexes. Their design also compares two biologically distinct cellular contexts, A549 lung cancer cells and THP-1 monocytic leukemia cells, allowing conserved and cell-type-enriched features of the CD38 neighborhood to be considered together.

This distinction between proximity and direct interaction is central to interpreting the work. NBID reports a spatially accessible protein environment around a target, not necessarily a stable binary complex. That makes it particularly suitable for studying dynamic surface organization, including membrane protrusions and tumor–endothelial contact zones.

Key Innovation from the Reference Study

The main innovation is a protein-of-interest-specific TurboID chimera. The authors use a nanobody that recognizes the target protein and fuse it to TurboID, a promiscuous biotin ligase. The resulting nanobody–TurboID chimera is directed to the extracellularly accessible target, where nearby proteins are labeled under live-cell conditions. Biotinylated material can then be enriched and identified by mass spectrometry.

This strategy addresses several limitations of antibody-dependent proximity labeling. Nanobodies are compact binding reagents, which may reduce steric interference at crowded membrane surfaces. In principle, the same TurboID module can be redirected to different surface proteins by changing the nanobody component. The approach therefore functions as a modular platform rather than a CD38-specific assay alone.

The study first validates the concept with an EGFR-targeting construct. Recovery of multiple established EGFR-associated proteins provides an internal test that the chimera can enrich a biologically meaningful neighborhood. The authors then apply a CD38-specific construct, identify candidate proteins by quantitative proteomics, and test selected candidates with microscopy and functional assays. This sequence—from platform validation to target discovery and biological testing—is a major strength of the experimental logic.

Methods and Experimental Design Insights

The workflow combines surface-directed proximity labeling with orthogonal measurements. This is important because a proteomics list alone cannot establish whether a candidate is spatially co-organized with CD38 or functionally relevant to migration.

Protocol Parameters

• Study-defined cellular models: The CD38-directed experiments used A549 lung cancer cells and THP-1 monocytic leukemia cells, while an EGFR-directed construct served as a validation system, according to the reference study.
• Targeting reagent: The experimental probe was a nanobody–TurboID chimera directed against a cell-surface protein. A matched target-specific design is preferable to inferring CD38 proximity from a generic membrane label.
• Proximity labeling: Labeling was performed in live adherent-cell cultures, followed by affinity capture of biotinylated proteins, trypsin digestion, and LC–MS/MS identification. The study-defined workflow should be distinguished from later optimization of labeling time, reagent amount, and cell density for a new model.
• Quantitative comparison: The authors combined proximity labeling with stable isotope labeling by amino acids in cell culture, or SILAC, to examine intercellular proximity at the tumor–endothelial interface. SILAC-based comparisons can help separate reproducible enrichment from changes caused by sample handling or protein abundance alone.
• Spatial validation: Total internal reflection fluorescence microscopy was used to determine whether selected proteins co-clustered with CD38 near the plasma membrane, particularly on surface protrusions.
• Functional testing: Transendothelial migration assays evaluated whether the molecular neighborhood identified by NBID corresponded to a measurable cancer-cell behavior. NAD+ treatment was also used to test whether this perturbation altered the CD38-proximal surfaceome in A549 cells.
• Workflow recommendation: For replication, include the targeting nanobody control, a TurboID or nonbinding control where appropriate, biological replicates, and independent validation of enriched candidates. These are general experimental safeguards rather than additional parameters reported by the reference study.

The combination of enrichment proteomics and TIRF imaging is especially informative. Mass spectrometry provides breadth across many candidates, whereas TIRF microscopy tests whether selected proteins occupy the same membrane-proximal structures as CD38. SILAC adds a quantitative layer for cell–cell interaction experiments, and migration assays connect molecular organization to phenotype.

Core Findings and Why They Matter

CD38-directed NBID enriched proteins associated with cell adhesion, extracellular-matrix organization, and lipid-raft-related membrane domains in both cellular settings. These categories suggest that CD38 is positioned within an organized surface network rather than functioning as an isolated enzymatic marker. In A549 cells, proteins related to Wnt signaling were also enriched, indicating that the CD38 neighborhood may be shaped by cell type and oncogenic state.

The authors report that NAD+ treatment did not significantly alter the CD38-proximal surfaceome in A549 cells. This result is useful because it separates the presence of CD38-associated proteins from one immediately detectable response to a metabolic substrate-related perturbation. It does not show that NAD+ biology is irrelevant to CD38, nor does it exclude changes outside the measured proximity window or under different cellular conditions.

Several candidates were further examined by TIRF microscopy. Their co-clustering with CD38 on membrane protrusions supports the interpretation that at least part of the proteomics signal reflects spatial organization at the cell surface. This observation is more specific than a simple increase in total cellular abundance and is consistent with the role of protrusive structures in adhesion and directional movement.

Functional assays showed that CD38 contributes to transendothelial migration of A549 cells. The result gives the surfaceome map biological context: proteins near CD38 may help organize a membrane state that supports interaction with endothelial barriers. The study does not imply that every enriched protein is required for migration, but it establishes a testable relationship between CD38 proximity and tumor-cell behavior.

The SILAC experiments provide a further advance by identifying CD38-associated cadherin adhesion complexes involving CDH2 and DSG2 at the tumor–endothelial interface. Other reported proximal candidates include MRC2, CD99, CTNNB1, and additional surface or membrane-associated proteins. Together, these data support a model in which CD38 is embedded in an adhesion network that may couple tumor-cell membrane organization to contact with endothelial cells. The importance of this finding lies less in a single newly named interactor than in the network-level view enabled by NBID.

Comparison with Existing Internal Articles

The internal overview Nanobody-TurboID Maps the CD38 Surfaceome presents the same study as an integrated platform combining proximity labeling, proteomics, microscopy, SILAC, and migration analysis. That framing is consistent with the reference paper, but the primary study adds important interpretive boundaries: NBID identifies proximal proteins rather than proving direct physical binding, and the CD38-associated network varies across cellular contexts.

The present analysis also places greater emphasis on experimental triangulation. EGFR validation supports the platform, TIRF microscopy tests membrane co-organization, SILAC addresses an intercellular setting, and transendothelial migration tests phenotype. These layers make the conclusions more persuasive than a protein list alone while still leaving mechanistic questions for targeted perturbation studies.

Limitations and Transferability

First, proximity labeling has a defined spatial and chemical detection range. A protein can be labeled because it is near the nanobody–TurboID probe without directly binding CD38. Conversely, a functionally important partner may be missed if it is inaccessible, weakly abundant, poorly biotinylated, or transient during the labeling interval. Candidate enrichment should therefore be treated as a starting point for validation.

Second, the main cell models do not represent every CD38-positive tumor or immune population. A549 and THP-1 cells differ in lineage, membrane composition, adhesion programs, and metabolic state. The presence of Wnt-related enrichment specifically in A549 cells illustrates why cell-context effects matter. Applying NBID to primary cells, organoids, suspension cultures, or tissue samples will require optimization of probe delivery, viability, labeling background, and quantitative normalization.

Third, the migration experiments establish a functional contribution of CD38 to transendothelial movement but do not fully resolve which candidate proteins mediate that effect. CDH2 and DSG2 are compelling components of the reported adhesion network, yet causal testing would require selective depletion, rescue, domain perturbation, or temporally controlled interference with individual candidates.

Finally, the article is a pre-proof version. Its findings provide early visibility into the study, but readers should consult the final version for any production-stage corrections or methodological clarifications. Even so, the central platform concept is transferable: a target-specific nanobody can potentially adapt TurboID to other accessible surface proteins, provided appropriate controls are used.

Why this cross-domain matters, maturity, and limitations

Surfaceome mapping and cell-division tracking answer different questions. NBID describes which proteins occupy a target-proximal molecular neighborhood, whereas a division-sensitive fluorescent label records the history of viable-cell proliferation. The internal guide CFDA-SE Workflows for Proliferation and Migration is useful in this context because it distinguishes phenotypic tracking from molecular interaction mapping.

This is a complementary but still limited bridge. A proliferation signal can help determine whether migrating populations differ in division history or viability, but it cannot demonstrate CD38 proximity, cadherin-complex assembly, or endothelial-interface organization. Conversely, the CD38 surfaceome study does not by itself quantify successive cell divisions. Combining the approaches is therefore most informative when each readout is analyzed independently and connected only through a defined experimental hypothesis.

Research Support Resources

For complementary viable-cell proliferation or migration tracking, researchers can use CFDA-SE (Carboxyfluorescein diacetate succinimidyl ester) (SKU C3430). The product information describes it as a cell-permeable, intracellular esterase-activated fluorescent labeling reagent whose signal is retained in cells and diluted during division. It may support a lymphocyte proliferation assay, fibroblast proliferation monitoring, natural killer cell proliferation, or bacterial proliferation assay alongside surfaceome experiments, provided the fluorescence readout is not interpreted as evidence of a molecular interaction. The reagent should be selected and validated for the specific cell type, labeling conditions, and flow cytometry proliferation tracking workflow.